Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cemiplimab + Isatuximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cemiplimab||Libtayo||REGN2810|SAR439684||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation (FDA.gov).|
|Isatuximab||Sarclisa||SAR650984|isatuximab-irfc||CD38 Antibody 7||Sarclisa (isatuximab-irfc) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056). Sarclisa (isatuximab-irfc) in combination with Pomalyst (pomalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received two or more prior therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03194867||Phase Ib/II||Cemiplimab + Isatuximab||Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients||Active, not recruiting|
|NCT03367819||Phase Ib/II||Isatuximab Cemiplimab + Isatuximab||Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies||Active, not recruiting|